Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis

NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical...